Amplistar Licenses Ovarian Cancer Genes From Johns Hopkins University

Breakthrough in the Development of the First Ovarian Cancer

Screening Test Announced



Apr 04, 2001, 01:00 ET from Amplistar, Inc.

    WINSTON-SALEM, N.C., April 4 /PRNewswire/ -- Amplistar, Inc., announced
 today the signing of an exclusive worldwide license agreement with Johns
 Hopkins University, to commercialize immunogenic ovarian cancer gene products
 for both diagnostic and therapeutic purposes.
     As presented in the latest issue (March 27, 2001) of the Proceedings of
 the National Academy of Sciences (PNAS), Drs. Richard Roden and Honami Naora,
 scientists in the department of pathology at Johns Hopkins University,
 recently identified ovarian-related gene products that produce an antibody
 immune response in ovarian cancer patients.  These antibodies were then used
 to develop a blood test for ovarian cancer.  Preliminary clinical results
 suggest that this blood test may be highly specific for ovarian cancer.
     Ovarian carcinoma is the most deadly cancer in women.  Over 14,000 women
 will die from ovarian cancer this year, in the U.S. alone.  The high mortality
 rate is primarily due to the silent nature of this disease, which is often not
 symptomatic until the cancer is widespread.  The survival rate for ovarian
 cancer is 28% when distant metastasis are present at the time of diagnosis,
 but jumps dramatically to 95% when diagnosed with only local spread present.
 Amplistar's screening test may offer a significant improvement in future
 survival rates by helping to "catch" ovarian cancer in it's early and most
 curable stages.
     Commenting on the agreement, Eric Button, CEO of Amplistar, said, "The
 addition of these gene products to our portfolio will greatly enhance our
 ability to fast-track development of an effective screening test for ovarian
 cancer.  We believe that the measurement of circulating antibodies to cancer
 represents an exciting and entirely novel scientific approach to the
 development of highly accurate blood tests, for the early detection of a wide
 variety of cancers.  In addition to our ovarian test development program, we
 possess an extensive collection of high-potential cancer antibody targets for
 several primary cancers including colon, lung, prostate, and breast."
 Exploiting their unique technology, Amplistar has begun development of routine
 blood tests for the early detection of these and other cancers.
     Amplistar, Inc. is a post-genomics company focused on the identification
 of antibody targets for the early detection and treatment of cancer.  The
 company utilizes both genomic and functional genomic information to identify
 and validate unique antibody targets -- a radically different discovery
 approach to the development of screening tests for cancer.
 
     This press release contains forward-looking statements, relating to
 management's expectations and beliefs about Amplistar's projected growth,
 which are based on preliminary information and management's assumptions.
 Amplistar's ability to achieve its projected growth is dependent on, and
 subject to a wide range of risks and uncertainties, many of which are outside
 of management's control.  Some of the most significant factors, alone or in
 combination, that could cause results to differ in material respects, include
 those relating to revenue and earnings expectations, reimbursement rates and
 coverage, the Company's maintenance of above-average quality of its product
 development, competitive pressures, unanticipated disagreements with joint
 venture partners, an unanticipated slowdown in the healthcare industry,
 changes in governmental regulation and an unanticipated loss of business.
 Accordingly, there can be no assurances that Amplistar will achieve its goals
 for expansion and growth.
 
 

SOURCE Amplistar, Inc.
    WINSTON-SALEM, N.C., April 4 /PRNewswire/ -- Amplistar, Inc., announced
 today the signing of an exclusive worldwide license agreement with Johns
 Hopkins University, to commercialize immunogenic ovarian cancer gene products
 for both diagnostic and therapeutic purposes.
     As presented in the latest issue (March 27, 2001) of the Proceedings of
 the National Academy of Sciences (PNAS), Drs. Richard Roden and Honami Naora,
 scientists in the department of pathology at Johns Hopkins University,
 recently identified ovarian-related gene products that produce an antibody
 immune response in ovarian cancer patients.  These antibodies were then used
 to develop a blood test for ovarian cancer.  Preliminary clinical results
 suggest that this blood test may be highly specific for ovarian cancer.
     Ovarian carcinoma is the most deadly cancer in women.  Over 14,000 women
 will die from ovarian cancer this year, in the U.S. alone.  The high mortality
 rate is primarily due to the silent nature of this disease, which is often not
 symptomatic until the cancer is widespread.  The survival rate for ovarian
 cancer is 28% when distant metastasis are present at the time of diagnosis,
 but jumps dramatically to 95% when diagnosed with only local spread present.
 Amplistar's screening test may offer a significant improvement in future
 survival rates by helping to "catch" ovarian cancer in it's early and most
 curable stages.
     Commenting on the agreement, Eric Button, CEO of Amplistar, said, "The
 addition of these gene products to our portfolio will greatly enhance our
 ability to fast-track development of an effective screening test for ovarian
 cancer.  We believe that the measurement of circulating antibodies to cancer
 represents an exciting and entirely novel scientific approach to the
 development of highly accurate blood tests, for the early detection of a wide
 variety of cancers.  In addition to our ovarian test development program, we
 possess an extensive collection of high-potential cancer antibody targets for
 several primary cancers including colon, lung, prostate, and breast."
 Exploiting their unique technology, Amplistar has begun development of routine
 blood tests for the early detection of these and other cancers.
     Amplistar, Inc. is a post-genomics company focused on the identification
 of antibody targets for the early detection and treatment of cancer.  The
 company utilizes both genomic and functional genomic information to identify
 and validate unique antibody targets -- a radically different discovery
 approach to the development of screening tests for cancer.
 
     This press release contains forward-looking statements, relating to
 management's expectations and beliefs about Amplistar's projected growth,
 which are based on preliminary information and management's assumptions.
 Amplistar's ability to achieve its projected growth is dependent on, and
 subject to a wide range of risks and uncertainties, many of which are outside
 of management's control.  Some of the most significant factors, alone or in
 combination, that could cause results to differ in material respects, include
 those relating to revenue and earnings expectations, reimbursement rates and
 coverage, the Company's maintenance of above-average quality of its product
 development, competitive pressures, unanticipated disagreements with joint
 venture partners, an unanticipated slowdown in the healthcare industry,
 changes in governmental regulation and an unanticipated loss of business.
 Accordingly, there can be no assurances that Amplistar will achieve its goals
 for expansion and growth.
 
 SOURCE  Amplistar, Inc.